CA
ARKG icon

Calton & Associates’s ARK Genomic Revolution ETF ARKG Stock Holding History

Calton & Associates’s Portfolio ARKG Stock Details ARKG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-3,098
Closed -$231K – 369
2021
Q3 		$231K Buy
3,098
+301
+11% +$25.3K 0.05% 349
2021
Q2 		$259K Buy
+2,797
New +$238K 0.05% 318
2021
Q1 		– Sell
-2,270
Closed -$212K – 402
2020
Q4 		$212K Buy
+2,270
New +$181K 0.04% 352

Other funds holding ARKG

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Calton & Associates's ARKG Position: Q4 2021 in Review

Calton & Associates sold out of ARK Genomic Revolution ETF (ARKG) in Q4 2021, closing a stake of 3,098 shares — an estimated $231K sold.

Calton & Associates first reported a position in ARKG in Q4 2020 and held it in 3 quarters. The position peaked at $259K in Q2 2021. 460 funds tracked by Wall St. Rank hold ARKG as of Q4 2021.

  • Calton & Associates reported no remaining ARK Genomic Revolution ETF position as of Q4 2021 after selling out during the quarter.
  • Calton & Associates sold 3,098 ARK Genomic Revolution ETF shares in Q4 2021, an estimated $231K.
  • Calton & Associates first reported a position in ARK Genomic Revolution ETF in Q4 2020 and held it in 3 quarters.
  • Calton & Associates's ARK Genomic Revolution ETF position peaked at $259K in Q2 2021.
  • 460 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q4 2021.

Based on Calton & Associates's 13F filing for Q4 2021, filed 13 Jan 2022.